Vaccine protection of chickens against antigenically diverse H5 highly pathogenic avian influenza isolates with a live HVT vector vaccine expressing the influenza hemagglutinin gene derived from a clade 2.2 avian influenza virus  by Kapczynski, Darrell R. et al.
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Vaccination  is  an  important  tool  in  the protection  of  poultry  against  avian  inﬂuenza  (AI).  For  ﬁeld  use,
the  overwhelming  majority  of  AI vaccines  produced  are  inactivated  whole  virus  formulated  into  an  oil
emulsion.  However,  recombinant  vectored  vaccines  are  gaining  use  for  their  ability  to  induce  protection
against  heterologous  isolates  and  ability  to  overcome  maternal  antibody  interference.  In these  studies,
we  compared  protection  of  chickens  provided  by  a turkey  herpesvirus  (HVT)  vector  vaccine  expressing
the  hemagglutinin  (HA) gene  from  a clade 2.2  H5N1  strain  (A/swan/Hungary/4999/2006)  against  homol-
ogous  H5N1  as  well  as heterologous  H5N1  and H5N2  highly  pathogenic  (HP) AI  challenge.  The  results
demonstrated  all vaccinated  birds  were  protected  from  clinical  signs  of  disease  and  mortality  following
homologous  challenge.  In addition,  oral  and  cloacal  swabs  taken  from  challenged  birds  demonstrated
that  vaccinated  birds  had lower  incidence  and  titers  of  viral  shedding  compared  to sham-vaccinated
birds.  Following  heterologous  H5N1  or  H5N2  HPAI  challenge,  80–95%  of birds  receiving  the  HVT  vector
AI  vaccine  at day  of age  survived  challenge  with  fewer  birds  shedding  virus  after  challenge  than  sham  vac-
cinated  birds.  In  vitro  cytotoxicity  analysis  demonstrated  that  splenic  T lymphocytes  from  HVT-vector-AI
vaccinated  chickens  recognized  MHC-matched  target  cells  infected  with  H5,  as  well  as  H6,  H7,  or  H9 AI
virus.  Taken  together,  these  studies  provide  support  for  the  use of  HVT  vector  vaccines  expressing  HA to
protect poultry  against  multiple  lineages  of  HPAI,  and  that  both  humoral  and cellular  immunity  induced
by  live  vaccines  likely  contributes  to  protection.
Published  by Elsevier  Ltd. This  is  an open  access  article  under  the  CC BY-NC-ND  license. Introduction
Since 1990s, there has been a signiﬁcant increase in the number
f highly pathogenic (HP) avian inﬂuenza (AI) outbreaks and also
n the number of birds involved in those outbreaks [1,2]. The most
otable of these recent HPAI outbreaks is a series of H5N1 outbreaks
tarted in China and Hong Kong since 1996, which then spread to
∗ Corresponding author at: Southeast Poultry Research Laboratory/ARS/USDA, 934
ollege Station Road, Athens, GA 30605, United States. Tel.: +1 706 546 3471;
ax:  +1 706 546 3161.
E-mail address: darrell.kapczynski@ars.usda.gov (D.R. Kapczynski).
ttp://dx.doi.org/10.1016/j.vaccine.2014.12.028
264-410X/Published by Elsevier Ltd. This is an open access article under the CC BY-NC-N(http://creativecommons.org/licenses/by-nc-nd/4.0/).
other parts of the world including South-East Asia, the Middle East,
Europe and Africa. These H5N1 viruses have become endemic in
several countries including China, Indonesia, Viet Nam and Egypt
[3]. Since 1996, H5N1 viruses underwent signiﬁcant antigenic drift
and the viruses have been classiﬁed into various clades accord-
ing to phylogenetic topology based on hemagglutinin (HA) gene
sequences according to WHO/OIE/FAO H5N1 Evolution Working
Group [4].
Vaccination has been considered a suitable and powerful tool
to support AI eradication or control programs in the endemically
infected countries in combination with other control measures
such as good biosecurity and monitoring programs [5–7]. When
used properly, vaccination has been shown to protect poultry
D license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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gainst clinical signs and death and markedly reduce virus shedding
n vaccinated birds, thereby reducing transmission of virus [8]. For
xample, the number of H5N1 outbreaks in Viet Nam dropped from
388 in 2003 to 45 in 2011 due to increased biosecurity, depopu-
ation and vaccine implementation [3]. It is known that antigenic
ifferences between vaccines and ﬁeld viruses affect vaccine efﬁ-
acy [9–11].
Immunity against AI is largely based on the induction of neu-
ralizing antibodies produced against the HA, although cytotoxic T
ymphocytes (CTL’s) have been reported as critical for clearance of
irus. Antibody production against a particular virus typically will
nly protect against homologous or antigenically matched isolates
2,12–14]. At least one study has demonstrated cross reactive AIV
TL’s in chickens against heterosubtypic AIV [15]. More recently, we
ave demonstrated broad cross reactive cellular immunity in birds
nfected with low pathogenic (LP) AI against different subtype of
IV [16].
Here, we tested a commercially available turkey herpesvirus
HVT) vector AI vaccine expressing the HA gene from a recent
lade 2.2 H5N1 virus to protect chickens against lethal HPAI chal-
enge. The efﬁcacy of this vaccine was tested against various HPAI
iruses including H5N1 viruses belonging to different clades and a
exican-lineage H5N2 virus.
. Materials and methods
.1. Viral strains and culture
Three HPAI strains were used in the vaccine-challenge studies:
/Whooper Swan/Mongolia/3/2005 H5N1 (SM05), A/chicken/West
ava Sbg/29/2007 H5N1 (CW07) and A/chicken/Queretaro/14588-
9/95 H5N2 (CQ95) (Supplemental Table 1). Four LPAI isolates
ere used for determination of cellular immunity in HVT-
ector-AI vaccinated birds to different subtypes of AI includ-
ng, A/turkey/Wisconsin/68 H5N9, A/chicken/CA/203/03 H6N2,
/turkey/VA/4259/02 H7N2 and A/chicken/NJ/12220/97 H9N2.
iruses were propagated and titrated in 9–11 days of embry-
nation, speciﬁc pathogen free (SPF) chicken eggs according to
tandard procedure [17].
.2. Vaccines
A HVT vector AI vaccine, Vectormune® AI (CEVA Animal Health,
enexa, KS) was constructed by inserting the HA gene of the
PAI A/Swan/Hungary/4999/2006 (SH06) H5N1 clade 2.2 strain
nto the genome of HVT FC-126 strain, hereby referred to rHVT-
u4999. The cleavage site of the HA gene was altered to a typical
leavage site sequence of LPAI virus strains. In experiment I, two
ifferent forms of HVT were used as the vaccine vector, a frozen,
ell-associated (ca) form or a lyophilized, cell-free (cf) form. In
xperiment III, a HVT vector AI vaccine containing the HA gene from
/turkey/Wisconsin/68 (H5N9) strain (rHVT-Wisc68) was used for
omparison. Cevac® Flu-Kem H5N2 vaccine (iH5N2) was  produced
y Ceva-Mexico, Cuarnavaca, and is an oil emulsion inactivated vac-
ine containing AI virus antigen A/Chicken/Mexico/232/94 strain
H5N2) (CM94) LPAI virus. Names and gene inserts of these vaccines
re summarized in Supplemental Table 2..3. Serologic assays
Hemagglutination inhibition (HI) assays were performed
ccording to standard protocol [18]. Homologous HPAI SM05
H5N1) virus, heterologous HPAI CW07 (H5N1) virus, and heterol-
gous HPAI CQ95 (H5N2) virus were used as antigen.e 33 (2015) 1197–1205
2.4. Statistical analysis
Kaplan–Meier survival curves were generated with Prism 5
(GraphPad Co., San Diego, CA). The Mantel–Cox log-rank test
was used to compare survival curves between two experimental
groups (Prism 5). Statistical differences in mean and standard error
between HI and virus titers were analyzed using Tukey one-way
ANOVA (Prism 5). The Fisher Exact test was  used for pair-wise com-
parison on frequency of virus isolation between groups (SigmaStat
2.0.3, SPSS Inc., Chicago, IL). Lower case letters indicate statistical
signiﬁcance between compared groups. All statistical tests were
performed using P < 0.05.
2.5. Animal challenge experiments
For experiments I and III, mixed-sex SPF, White Leghorn
(WL) chickens were obtained from Charles River Laboratories
(Wilmington, MA). For experiment II, mixed-sex SPF broiler (White
Rock) chickens from Southeast Poultry Research Laboratory were
used. Chickens were housed in a BSL2 facility at the University of
Georgia, Poultry Diagnostic Research Center, Athens, Georgia for
vaccination and grow out. Chickens were transferred to a BSL3
enhanced facility at Southeast Poultry Research Laboratory for chal-
lenge. Birds were maintained in Horsfall isolation units with feed
and water ad libitum.
Serum samples were taken via wing vein prior to vaccination,
prior to challenge and 14 days post-challenge (dpc), and were
stored at −20 ◦C. Oro-pharyngeal and cloacal swab samples were
collected on days 2 and 4 post-challenge (experiments I and II)
or days 3 and 6 post-challenge (experiment III) for virus isola-
tion. Swab samples were placed in 2.0 ml  BHI broth as previously
described [2]. Following challenge, groups were monitored twice
daily for 14 days for clinical signs, and those with severe clinical
signs disease were humanely euthanized by approved protocol and
counted as mortalities for that day.
2.5.1. Experiment I – clinical protection of vaccinated SPF
chickens against homologous H5N1 challenge
Day of age SPF WL chicks were divided into three groups. The
ﬁrst group was  vaccinated with the cell-associated form of rHVT-
Hu4999 (1500 pfu) and the second group received the cell-free form
of rHVT-Hu4999 (1500 pfu). The last group was inoculated with
only vaccine diluent and served as a challenge control. At 6 weeks of
age, chickens were challenged intranasally with HPAI SM05 H5N1
clade 2.2 virus at 106 mean embryo infectious dose (EID50) per
chicken. Thirty chickens in the cell-associated rHVT-Hu4999 group,
20 chickens in the cell-free rHVT-Hu4999 group and 10 chickens in
the challenge control group were challenged.
2.5.2. Experiment II – clinical protection against heterologous
H5N1 HPAI of Indonesian origin
Day of age SPF broiler (white rock) chicks were divided into
four groups. The ﬁrst group was vaccinated with rHVT-Hu4999 ca
(2000 pfu) at day of age. The second group was  vaccinated with
rHVT-Hu4999 ca (2000 pfu) at day of age and then with iH5N2 at
10 days of age. The third group received only iH5N2 vaccine at 10
days of age. The last group received PBS and was used as a challenge
control. At 4 weeks of age, chickens were challenged intranasally
with HPAI CW07 H5N1 clade 2.1.3 virus at 106 EID50 per chicken.
2.5.3. Experiment III – clinical protection of vaccinated SPF
chickens after heterologous H5N2 HPAI of Mexican origin
In this study, SPF WL  chickens were divided into three groups.
The ﬁrst group received rHVT-Hu4999 ca (1500 pfu), the second
group received rHVT-Wisc68 ca (1500 pfu), and the third group was
accine 33 (2015) 1197–1205 1199
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Fig. 1. Kaplan–Meier survival plots for protection of vaccinated chickens against
homologous or heterologous HPAI H5 subtype challenge. Survival of chickens from
unvaccinated (Sham) or vaccinated with rHVT-Hu4999 in cell-associated (ca) or
cell-free (cf) form at 1 day-of-age and challenge at 6 weeks with homologous HPAI
H5N1 in experiment I (A). Survival of chickens vaccinated with either rHVT-Hu4999
at  one day-of-age, inactivated (i) H5N2 (CM94) at 10 days-of-age, or a combination
of  both. Birds were challenged with heterologous HPAI of Indonesian H5N1 (CW07)
(clade 2.1.3) at 4 weeks-of-age in experiment II (B). Survival of chickens following
vaccination with rHVT-Hu4999 or rHVT-Wisc68 at day-of-age with heterologous
challenge from Mexican lineage H5N2 (CQ94) at 4 weeks-of-age in experiment III
(C). Different numbers next to survival lines within an individual graph representD.R. Kapczynski et al. / V
noculated with only vaccine diluent and served as a challenge con-
rol. At 4 weeks of age, chickens were challenged intranasally with
PAI CQ95 H5N2 virus at 106 EID50 per chicken. Twenty chickens
n the vaccinated groups and 10 chickens in the challenge control
roup were challenged.
.6. Cytotoxic T-lymphocyte (CTL) lysis of avian inﬂuenza
nfected lung-cell cultures
Major histocompatibility complex (MHC)-deﬁned B2B2 SPF
hickens (gift from Avian Disease Oncology Laboratory, ARS,
ast Lansing, MI)  received 1500 pfu rHVT-Hu4999 at 1 day of
ge. At 4 weeks of age, splenic lymphocytes were puriﬁed over
icoll–Hypaque. Lung cell cultures from 2-week-old B2B2 SPF birds
ere obtained as previously described and used as target cells for
TL assay [15]. Lung cells were infected with either H5N9, H6N2,
7N2 or H9N2 LPAI at an MOI  of 2 for 16 h prior to testing. Various
atios of lymphocytes were added and centrifuged onto target cells.
TL activity was monitored using the CytoTox96 nonradioactive
ssay (Promega), as previously described [15].
.7. HA sequence analysis
Avian inﬂuenza HA amino acid sequences were obtained from
enBank and Inﬂuenza Research Database (http://www.ﬂudb.org/
rc/home.do?decorator=inﬂuenza). Comparison of HA sequence
rom isolates used in these studies to putative H5(246–260) MHC
lass I and II T cell epitope identiﬁed in A/turkey/Ireland/1378/83
H5N8) were performed using Jotun Hein method with MegAlign
DNA STAR Lasergene 8, Madison, WI)  [19].
. Results
.1. Experiment I – comparison of cell-associated or cell-free
HVT-Hu4999 vaccine-induced protection of chickens against
atched homologous H5N1 HPAI challenge
Efﬁcacy of rHVT-Hu4999 vaccine against challenge with homol-
gous H5N1 HPAI virus was evaluated. The HPAI SM05 H5N1 clade
.2 virus used for challenge has 100% HA gene sequence homology
ith the vaccine. All chickens vaccinated subcutaneously at day
f age with rHVT-Hu4999, survived the homologous challenge at 6
eeks of age, while all of the challenge control chickens died within
 days (Fig. 1A). No clinical signs were observed in the vaccinated
roups.
Elevated HI titers were detected in both of the rHVT-Hu4999
accinated groups before challenge with mean titers of 25.1 for the
f group and 26.3 for the ca group (Fig. 2A). After challenge, mean
I titer of the cf group increased to 26.4, while mean HI titer of the
a group decreased to 25.6 (Fig. 2B).
The rHVT-Hu4999 vaccinated chickens shed little challenge
irus at 2 and 4 dpc. From oro-pharyngeal swabs at 2 dpc, virus
as isolated from 4/30 (13%) chickens in the ca rHVT-Hu4999
roup and 3/20 (15%) chickens in the cf rHVT-Hu4999 group,
ith minimal virus titers (101–103 EID50/ml), while all the chal-
enge controls shed signiﬁcant amounts (105–107 EID50/ml) of virus
Fig. 3 and Table 1). No virus was isolated from cloacal swabs of the
HVT-Hu4999 vaccinated chickens at 2 dpc, while all the challenge
ontrols shed virus.
.2. Experiment II – protection following challenge with
ndonesian origin H5N1 HPAIEfﬁcacy of rHVT-Hu4999 vaccine against heterologous CW07
5N1 clade 2.1.3 virus of Indonesian origin was evaluated in SPF
roilers. Sequence similarity of the HA genes between the vaccinestatistical difference in survival curves between the vaccine groups (p < 0.05).
insert SH06 and the CW07 virus was 93%, but only 87% and 84%,
respectively, to the CM94 isolate in the iH5N2 vaccine. We  used
broiler chickens in this trial because broilers have been affected
greatly by H5N1 HPAI as well as layer chickens. Also, we conducted
challenge at 4 weeks of age rather than 6 weeks of age in experiment
I, in order to see if the HVT vector AI vaccine provides protective
immunity at an earlier time than 6 weeks of age. After the challenge,
1200 D.R. Kapczynski et al. / Vaccine 33 (2015) 1197–1205
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Fig. 2. Individual HI titers (log2) and standard error for bird groups in experiment
I,  (A) 5 weeks post-vaccination (prechallenge) and (B) 2 weeks post-challenge. Sta-
tistical signiﬁcance between mean titers was determined with ANOVA using the
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Fig. 3. Viral titers from oral (A) and cloacal swabs (B) on day 2 post-challenge
in  experiment I. Birds were vaccinated with a single dose rHVT-Hu4999 in cell-
associated (ca) or cell-free (cf) form at one day-of-age and challenge at 6 weeks
with homologous HPAI H5N1. Viral titers are expressed as log10 EID50 per milliliter.
T
F
sukey’s multiple comparison test (p < 0.05). Sham: unvaccinated/HAPI challenged;
HVT-Hu4999 cell associated (ca) vaccinated/HPAI challenged; rHVT-Hu4999 cell
ree (cf) vaccinated/HPAI challenged. NS = no signiﬁcant difference.
ll the challenge controls died within 2 days (Fig. 1B). In the group
accinated with rHVT-Hu4999 only, 80% (16/20) of the chickens
urvived. When rHVT-Hu4999 vaccinated chickens received boost
ith iH5N2 vaccine at 10 days of age, protection increased to 90%
18/20). Only one bird in a group that received only iH5N2 vacci-
ation at 10 days of age survived. Survived chickens did not show
ny clinical signs of AI.
HI titers were evaluated using homologous SM05 antigen and
eterologous CW07 antigen (Fig. 4). When the homologous antigen
as used, rHVT-Hu4999, either with or without boost with iH5N2
able 1
requency of virus isolation from groups of chickens in experiment I after homologous
amples  were collected on days 2 and 4 post-challenge from birds vaccinated with cell-a
Group 2 dpca
Oropharyngeal swab Cloaca
1: rHVT-Hu4999 ca 4/30a 0/30a
2:  rHVT-Hu4999 cf 3/20a 0/20a
3:  Sham 6/6b 6/6b
a # Shedding virus/total at 2 days post-challenge. Lower case letters indicate a signiﬁca
b # Shedding virus/total at 4 days post-challenge.The  lower limit of detection is 0.9 log10 EID50 per milliliter. Statistical signiﬁcance
between mean titers was determined with ANOVA using the Tukey’s multiple com-
parison test (p < 0.05). NS = no signiﬁcant difference.
vaccine, induced average HI titers of 25–26 prior to challenge. HI
titers were much lower with the heterologous antigen with aver-
age between 21 and 22. iH5N2 alone induced lower HI titers than
rHVT-Hu4999, with average titers of 21.7 against the homologous
antigen and 20.2 against the heterologous antigen. After challenge,
signiﬁcant HI increase was observed with all the groups.
Virus shedding from rHVT-Hu4999 vaccinated chickens, with
or without boost with iH5N2 vaccine was  signiﬁcantly decreased
compared to the challenge control and iH5N2 alone (Fig. 5
 H5N1 challenge with A/whooper swan/Mongolia/3/2005. Oral and cloacal swab
ssociated (ca) or cell-free (cf) rHVT-Hu4999.
4 dpcb
l swab Oropharyngeal swab Cloacal swab
0/30 0/30
1/20 0/20
Not done Not done
nt difference among groups by Fisher’s exact test (p < 0.05).
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W07 antigen (B), (D). Titers obtained prechallenge (A), (B) and 2 weeks post-challe
NOVA using the Tukey’s multiple comparison test (p < 0.05). NS = no signiﬁcant dif
nd Supplemental Table 3). At 2 dpc from oro-pharyngeal swabs,
here was a 3 log10 reduction in the rHVT-Hu4999 groups com-
ared to the challenge control and 1 log10 reduction compared
o iH5N2 alone. Both differences were statistically signiﬁcant.
here was no difference between rHVT-Hu4999 alone and rHVT-
u4999 + iH5N2.
.3. Experiment III – clinical protection of vaccinated chickens
gainst heterologous H5N2 HPAI challenge
Finally, efﬁcacy of rHVT-Hu4999 vaccine against heterolo-
ous H5N2 HPAI challenge was evaluated. Homology of the HA
enes between the insert SH06 strain and HPAI CQ95 H5N2
irus was 82%. In this trial, rHVT-Wisc68 expressing HA gene of
/turkey/Wisconsin/68 H5N9 (TW68) strain was also used for com-
arison. The HA gene of the TW68 strain was 91% similar to that of
PAI CQ95 H5N2 virus. After challenge at 4 weeks of age, all of
he challenge control chickens died by 6 dpc. In the rHVT-Hu4999
accinated group, 95% (19/20) of the chickens survived the chal-
enge (Fig. 1C). All chickens vaccinated with rHVT-Wisc68 survived.
urvived chickens did not show any clinical signs of AI.
Because previous experiments demonstrated HI titers after
hallenge to the homologous challenge virus (Fig. 2B), HI titers were
valuated using heterologous CQ95 H5N2 virus as an antigen. Both
HVT-Hu4999 and rHVT-Wisc68 induced somewhat increased HI
iters before challenge (Fig. 6A), although HI titers were not as high
s what were observed when using the homologous antigen. Titers
n rHVT-Wisc group were higher at mean titer of 24.5 than those in titers were evaluated using homologous SM05 antigen (A), (C) and heterologous
), (D) are shown. Statistical signiﬁcance between mean titers was  determined with
e.
rHVT-Hu4999 group at 22.8 probably because TW68 strain is more
similar to the CQ95 H5N2 strain than the SH06. HI titers increased
to 28 after challenge (Fig. 6B).
Both rHVT-Hu4999 and rHVT-Wisc68 reduced challenge virus
shedding signiﬁcantly (Supplemental Table 4). At 3 dpc, only 2 out
of 19 chickens (11%) in the rHVT-Hu4999 group shed virus from
oro-pharyngeal swabs and none in the rHVT-Wisc68, while 6 out
of 7 (86%) of the challenge controls shed virus.
3.4. Cross reactive CTL response from rHVT-Hu4999 vaccinated
birds
To examine cellular immunity induced by the rHVT-Hu4999
vaccine, we evaluated the in vitro CTL activity of splenic T-cells
recovered from vaccinated birds. Splenic T cells demonstrated the
highest level of lysis against H5 AIV infected target cells (Fig. 7).
At an effector:target (E:T) ratio of 40:1, 67% of target cells infected
with H5N9 AIV were lysed. Lysis of target cells was also observed
heterologous subtype AIVs. Decreased lysis was  observed in H6, H7
or H9 infected target cells, demonstrating a decrease in speciﬁcity
to the heterologous viruses. Splenic T cells did not lyse uninfected
target cells, and the percent of spontaneous lysis was <5% (data not
shown).3.5. Sequence comparison of HA H5(246–260) peptide
Since vaccination with live virus stimulates cellular immunity,
we sought to compare previously published MHC  I and II amino
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Andonesian CW07 H5N1 virus at 106 EID50. Viral titers from oral (A), (C) and cloacal (
og10 EID50 per milliliter. Statistical signiﬁcance between mean titers was determin
ifference.
cid residues found in the HA of A/turkey/Ireland/1378/83 H5N8
o the avian inﬂuenza viruses used in these studies. The MHC
/II peptide, H5(246–260), shared similarity between 50% and 88%
ith the HA from the various H5, H6, H7, H9 isolates tested here.
ot surprisingly, the highest similarity was observed with the H5
able 2
equence alignment of known MHC  I and II peptide from HA of A/turkey/Ireland/1378/83
Peptide sequencea Virus strain 
WTILKPSDTINFESN A/turkey/Ireland/1378/83 
WTILKPNDAINFESN A/Swan/Hungary/4999/06 
WTILKPNDAINFESN A/Whooper Swan/Mongolia/3/05 
WTILKPNDAINFESN A/chicken/West Java Sbg/29/07 
WTILRPNDSINFEST A/chicken/Queretaro/14588-19/95 
WTILRPNDAISFESN A/turkey/Wisconsin/68 
WSVLKPGETLNVSEN A/chicken/California/203/03 
WLLLDPNDTVTFTFN A/turkey/Virginia/4259/02 
WSVLKPGQTLRVRSN A/chicken/New Jersey/12220/97 
a Bold-faced residues represent sequences found at same position in all isolates 
/turkey/Ireland/1378/83 sequence.) swabs are expressed as log10 EID50 per milliliter. The lower limit of detection is 0.9
h ANOVA using the Tukey’s Multiple Comparison Test (p < 0.05). NS = no signiﬁcant
viruses at 88% for the H5N1 and H5N2 subtypes which correlated
with increased CTL activity (Table 2). Interestingly, three residues,
tryptophan (W)  at position 246, leucine (L) at position 249, and
proline (P) at position 251 were conserved in the HA of all viruses
examined.
 (H5N8) with H5 HA epitopes from isolates used in these studies.
Subtype Similarity
H5N8 100
H5N1 88
H5N1 88
H5N1 88
H5N2 75
H5N9 75
H6N2 50
H7N2 50
H9N2 50
examined. Underlined residues represent differences in peptide sequence to
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. Discussion
Avian inﬂuenza remains one of the most important zoonotic
iseases as evidenced by the HP H5N1 viruses that evolved in
outheast Asia since 1996, and recent outbreaks of H7N9 in
hina, and H7N7 in Italy [20–23]. Although vaccines such as oil-
djuvanted whole inactivated AI virus antigens have been used in
umerous countries as an aid in control, efﬁcacy is not optimumean titers was determined with ANOVA using the Tukey’s multiple comparison test
unless there is antigenic match between the vaccine and ﬁeld strain
[11]. Additionally, interference with maternally derived antibodies
can render inactivated vaccines impotent [24].
The results presented here demonstrate that a single vacci-
nation at day of age with either cell-associated (ca) or cell-free
(cf) form of rHVT-Hu4999 provided complete clinical protection
against homologous HPAI challenge. In all instances, virus shed-
ding was also signiﬁcantly reduced compared to sham-vaccinated
1204 D.R. Kapczynski et al. / Vaccin
10:1 20:1 40:1
0
20
40
60
80
H5
H6
H7
H9
Effector cells:Target cells
%
 L
ys
is
Fig. 7. Cytotoxicity of splenic lymphocytes recovered from B2B2 chickens vacci-
nated with rHVT-Hu4999. Effector cells were taken from spleens of chickens at
4-weeks post-vaccination. Target B2B2 lung cells (target cells) were infected with
e
C
c
c
d
h
o
i
t
t
t
a
I
w
v
o
c
v
s
e
c
h
n
p
i
b
g
s
H
r
t
i
a
i
d
H
c
c
c
t
a
s
[
[
[
[
[
ens against highly pathogenic Hong Kong H5N1 avian inﬂuenza. Avian Disither H5N9, H6N2, H7N2 or H9N2 LPAI for 16 h prior to addition of effector cells.
TL  activity was measured by release of lactic dehydrogenase in lysed cells.
ontrols. Because virus shedding from infected birds is a primary
ause of transmission to susceptible cohorts, the decreased shed-
ing would also reduce transmission potential. Previous research
as demonstrated the efﬁcacy of this vector vaccine against homol-
gous challenge from clade 2.2.1 Egyptian HPAI H5N1 viruses [10].
The cell-associated form of HVT vaccine is considered more
mmunologically efﬁcacious than the cell-free form especially in
he presence of maternally derived antibodies [25]. Therefore, we
ested both forms of rHVT-Hu4999 in this experiment because
he cell-free form has an advantage in transportation and stor-
ge over the cell associated form, which requires liquid nitrogen.
n this experiment, both forms protected completely and there
as no difference in protection between the two forms of the
accine.
Our results also demonstrate that rHVT-Hu4999 is capable
f providing heterologous protective immunity against different
lades of H5N1 and an unrelated H5N2 isolate from Mexico. The
accine induced immunity that included signiﬁcant reduction in
hedding in those groups compared to the challenge control. How-
ver, the signiﬁcant increase in HI titers following heterologous
hallenge is indicative of increased virus replication compared to
omologous challenge. In addition, by changing the HA compo-
ent of the vaccine to the Wisc68 HA, we demonstrated complete
rotection with minimal virus shedding against Mexican H5N2
solate.
rHVT-Hu4999 elicited positive HI antibodies with average titers
etween 25 and 26 prior to challenge, when using the homolo-
ous HA antigen. However, when using heterologous HA antigens
uch as CQ95 H5N2 virus and CW07 H5N1 virus, much lower
I titers with average between 21 and 23 were observed with
HVT-Hu4999. Nonetheless, rHVT-Hu4999 provided good protec-
ion against challenge with those heterologous viruses, which may
ndicate contribution from other immune factors in protection
gainst AIV than antibodies.
Little is known about the induction of cellular mediated
mmunity (CMI) against AIV in chickens. Seo and Webster [15]
emonstrated adaptive transfer of the AIV-primed T-cells from
9N2-infected birds protected naïve-birds against lethal H5N1
hallenge (A/Chicken/Hong Kong/97). HVT is a known inducer of
ell-mediated immunity and has been shown to induce speciﬁc
ell-mediated immunity [26,27]. Our studies agree with those, in
hat speciﬁc cellular immunity against the HA was  observed.Our studies also demonstrate cross reactive CTL activity induced
gainst the HA by the HVT vector vaccine that recognized different
ubtypes of AIV. Recently Haghighi et al. [19] identiﬁed a T cell
[e 33 (2015) 1197–1205
epitope from an H5 AIV recognized by chicken T cells. Interest-
ingly, this epitope was  determined to be on the HA protein and was
recognized by both CD4+ and CD8+ chicken T cells. Amino acid
alignment of the HA from isolates used in our studies clearly
demonstrated the presence of this peptide motif. However, further
research is necessary to conﬁrm that these epitopes are responsible
for the observed CMI  induced by the rHVT-Hu4999 vaccine.
In conclusion, this study demonstrated that HVT vector AI vac-
cine expressing HA gene of A/Swan/Hungary/4999/2006 (H5N1)
provided protection against a wide range of HP AIV including H5N1
clade 2.2 and clade 2.1.3 viruses and a H5N2 virus. Although anti-
body titers were not predictive for protection against heterologous
challenge, we  observed signiﬁcant protection from challenge that
appears to be aided in some part to broadly cross reactive cellular
immunity. This vaccine appears to have the potential to be a use-
ful tool to control multiple lineages of HPAI along with biosecurity
measures and monitoring.
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